SANTA CLARA, Calif. & SEOUL, South Korea
Agilent Technologies Inc. (NYSE: A) and Seoul National University Hospital, one of Korea’s top medical centers, today announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
“There are gaps in the medical industry that hamper the quality of care we can provide to patients,” said Prof. Byung-Hee Oh, president and CEO, Seoul National University Hospital. “One area we want to address is the development of biomarkers for early detection and effective monitoring of a range of diseases.”
“Our hospital is pleased to collaborate with Agilent, the premier test and measurement company, to help us stretch the horizons of medical research in order to improve the lives of people in Korea and around the world,” he said.
Under the agreement, the hospital’s Department of Laboratory Medicine will use the Agilent 6460 Triple Quadrupole LC/MS system as well as Agilent’s support services and application expertise. The hospital is committed to creating and maintaining an optimal environment for new biomarkers to be identified and tested rigorously by highly sensitive yet robust instruments.
“We are privileged to partner with Seoul National University Hospital, which has a strong tradition of innovation and quality care for customers,” said Agilent’s Rod Minett, general manager, Life Sciences, South Korea and the South Asia-Pacific region. “Through this collaboration, we hope to establish more effective and varied verifications system for the medical and life sciences industries.”
About Seoul National University Hospital
Seoul National University Hospital has been looking after public health over the past 100 years, leading the development of medicine in Korea. It was established in 1885 as Korea’s first national hospital under the name of Kwang Hye Won. It became the affiliate hospital for Seoul National University’s College of Medicine and College of Dentistry before being recognized as a special corporate body under the name of Seoul National University Hospital. Today, the hospital is comprised of the Main Hospital, the Children’s Hospital, the Caner Hospital, the Dental Hospital, and the Clinical Research Institute. For more information, please visit www.snuh.org/english.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,500 employees serve customers in more than 100 countries. Agilent had net revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.
CONTACT
Agilent
Sui-Ching Low, +65 6215 8975
sui-ching_low@agilent.com
or
SNUH
Jeong
Jun Park, +82 2 2072 0077
sogncol@daum.net
